Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

 

Corporate Presentation IDEAYA Highlights Investor Alerts

 
Recent News
Feb 20, 2024

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study...

Feb 1, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Jan 26, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 25, 2024, the...

All Releases

Stock Info
NASDAQIDYA

Stock Information

Events
Wednesday, February 21, 2024
11:00am EST

Fireside chat with Darrin Beaupre, Chief Medical Officer and Michael White, Chief Scientific Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst

Wednesday, February 14, 2024
1:20pm EST

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst

All Events

WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS

Close Menu